Insider trade

Richard E Lowenthal, CEO at Ars Pharmaceuticals, sold ~$755K of Ars Pharmaceuticals shares.

~$755K
Approx. value · 45K sh @ $16.76
1.3M
Holds after · shares reported
Traded
Nov 12, 2024
Filed
Nov 14, 2024

What stands out in this filing

  • The sale was 3.3% of the shares this insider held before it; the filing reports 1,301,449 shares, held indirectly afterwards.
  • 45,045 shares at an average of $16.76 each, as reported on the form.
  • Footnote references a pre-arranged trading plan (Rule 10b5-1).

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 8, 2024Insider · 2 peopleInsiders: 4 sales (~$2.8M)
  2. Oct 15, 2024Insider · 2 peopleInsiders: 6 sales (~$3.0M)
  3. Oct 16, 2024InsiderCFO sold ~$200K of SPRY shares in the open market
  4. Nov 11, 2024Insider · 1 personInsiders: 4 sales (~$9.5M)
  5. Nov 12, 2024 · this disclosureInsiderCEO sold ~$755K of SPRY shares in the open market

What came next

  1. Nov 12, 2024Insider · 3 peopleInsiders: 11 sales (~$3.2M)
  2. Nov 19, 2024Insider · 2 peopleInsiders: 4 sales (~$2.8M)
  3. Nov 25, 2024InsiderOfficer sold ~$459K of SPRY shares in the open market
  4. Nov 26, 2024InsiderOfficer sold ~$593K of SPRY shares in the open market
  5. Nov 27, 2024InsiderOfficer sold ~$360K of SPRY shares in the open market
  6. Dec 2, 2024Insider · 3 peopleInsiders: 4 sales (~$2.0M)
  7. Dec 3, 2024Insider · 2 peopleInsiders: 2 sales (~$1.8M)
  8. Dec 4, 2024Insider · 3 peopleInsiders: 3 sales (~$919K)
  9. Dec 5, 2024InsiderOfficer sold ~$702K of SPRY shares in the open market
  10. Dec 6, 2024InsiderOfficer sold ~$712K of SPRY shares in the open market
  11. Dec 10, 2024Insider · 3 peopleInsiders: 5 sales (~$3.3M)
  12. Dec 11, 2024InsiderOfficer sold ~$186K of SPRY shares in the open market
  13. Dec 12, 2024Insider · 2 peopleInsiders: 2 sales (~$1.7M)
  14. Dec 13, 2024InsiderOfficer sold ~$329K of SPRY shares in the open market
  15. Dec 17, 2024Insider · 2 peopleInsiders: 4 sales (~$2.3M)
  16. Jan 6, 2025InsiderDirector sold ~$555K of SPRY shares in the open market
  17. Feb 3, 2025InsiderDirector sold ~$616K of SPRY shares in the open market
  18. Mar 5, 2025InsiderDirector sold ~$4.4K of SPRY shares in the open market
  19. Mar 6, 2025InsiderDirector sold ~$556K of SPRY shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Ars Pharmaceuticals

For Ars Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SPRY page.

Other recent filings by Richard E Lowenthal, PRESIDENT AND CEO

The full history of Richard E Lowenthal, PRESIDENT AND CEO is on the profile page.

How this filing works

Explore the data

Common questions

Which Ars Pharmaceuticals (SPRY) insider traded, and how much?

Richard E Lowenthal, CEO at Ars Pharmaceuticals, sold ~$755K of Ars Pharmaceuticals shares. 45K shares at $16.76.

When did it happen, and when was it made public?

Traded: Nov 12, 2024. Filed: Nov 14, 2024. That is 2 days between the two dates.

What stands out in this filing?

The sale was 3.3% of the shares this insider held before it; the filing reports 1,301,449 shares, held indirectly afterwards. 45,045 shares at an average of $16.76 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Ars Pharmaceuticals recently?

For Ars Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the SPRY page.

Does this mean SPRY stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Ars Pharmaceuticals

Everything OQRO holds on this company is on its SPRY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data